MARKET

XCUR

XCUR

EXICURE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.670
+0.060
+3.73%
Closed 16:00 10/23 EDT
OPEN
1.640
PREV CLOSE
1.610
HIGH
1.700
LOW
1.620
VOLUME
105.97K
TURNOVER
--
52 WEEK HIGH
3.840
52 WEEK LOW
0.9573
MARKET CAP
145.67M
P/E (TTM)
-6.5260
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Exicure Announces Phase 1b Poster Presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
Exicure announced an upcoming poster presentation for cavrotolimod (AST-008), at the 35th Anniversary Annual Meeting of SITC.
Business Wire · 4d ago
Exicure Announces Phase 1b Poster Presentation At The Society For Immunotherapy Of Cancer 35th Anniversary Annual Meeting Nov. 9-14
Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing proprietary spherical nucleic acid (SNA™) technology, announced an upcoming poster presentation for its intratumoral
Benzinga · 4d ago
Exicure to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference
Exicure announced a presentation at the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5, 2020.
Business Wire · 10/05 12:00
Exicure secures up to $25M in debt financing
Exicure (XCUR) has closed a $25M senior secured term loan with interest payments only for 24 months. The company has received $17.5M of proceeds, and an additional $7.5M can be drawn
Seekingalpha · 10/01 11:19
Exicure Secures Debt Facility for Up to $25.0 Million
Exicure today announced it has entered into a $25.0 million senior secured term loan with MidCap Financial Trust and Silicon Valley Bank.
Business Wire · 10/01 11:00
Here's Why We're Not At All Concerned With Exicure's (NASDAQ:XCUR) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Simply Wall St. · 09/22 20:31
Exicure Presents Promising Interim Results from Ongoing Phase 1b/2 Trial of Cavrotolimod at Virtual KOL Event Today
Business Wire · 09/16 12:00
Exicure to Present at Upcoming Conferences
Exicure today announced presentations at two upcoming conferences during the month of September.
Business Wire · 09/10 11:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XCUR. Analyze the recent business situations of EXICURE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XCUR stock price target is 10.50 with a high estimate of 18.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 78
Institutional Holdings: 41.32M
% Owned: 47.37%
Shares Outstanding: 87.23M
TypeInstitutionsShares
Increased
18
5.46M
New
35
-600.00K
Decreased
11
3.02M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.58%
Pharmaceuticals & Medical Research
+0.69%
Key Executives
Chairman/Independent Director
Timothy Walbert
Chief Executive Officer/Chief Financial Officer/Secretary/Director
David Giljohann
Chief Operating Officer
Matthias Schroff
Director
Chad Mirkin
Independent Director
Jeffrey Cleland
Independent Director
Bosun Hau
Independent Director
Helen Kim
Independent Director
Bali Muralidhar
Independent Director
Jay Venkatesan
Independent Director
David Walt
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About XCUR
Exicure, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for immuno-oncology, genetic disorders and other indications based on its Spherical Nucleic Acid (SNA) technology. SNA is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Its pipeline includes AST-008, XCUR-FXN and XCUR17. AST-008 product is a toll-like receptor 9 agonist designed to activate the innate immune system and induce a potent anti-cancer immune response, especially in combination with checkpoint inhibitors. XCUR-FXN is a preclinical program for the treatment of Friedreich’s ataxia (FA). XCUR17 is being developed for inflammatory disorders, netherton syndrome and hair loss disorders. XCUR17 is an SNA that targets the mRNA that encodes interleukin 17 receptor alpha (IL-17RA).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Exicure Inc stock information, including NASDAQ:XCUR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XCUR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XCUR stock methods without spending real money on the virtual paper trading platform.